



Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Required to respond to a collection of information unless it contains a valid OMB

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code 2 (if known)			
[Handwritten marks]	1	US-4496556	01/29/1985	Orentreich	
	2	US-4695465	09/22/1987	Kigasawa, et al.	
	3	US-4863970	09/05/1989	Patel, et al.	
	4	US-4946870	08/07/1990	Partain, et al.	
	5	US-5053227	10/01/1991	Chiang, et al.	
	6	US-5059603	10/22/1991	Rubin	
	7	US-5152997	10/06/1992	Ebert, et al.	
	8	US-5256652	10/26/1993	El-Rashidy	
	9	US-5324521	06/28/1994	Gertner, et al.	
	10	US-5332577	07/26/1994	Gertner, et al.	
	11	US-5340586	08/23/1994	Pike, et al.	
	12	US-5346901	09/13/1994	Bell, et al.	
	13	US-5362497	11/08/1994	Yamada, et al.	
	14	US-5413794	05/09/1995	Suzuki, et al.	
	15	US-5460820	10/24/1995	Ebert, et al.	
	16	US-5550107	08/27/1996	Labrie	
	17	US-5648350	07/15/1997	De Lignieres	
	18	US-5719197	02/17/1998	Kanios, et al.	
	19	US-5723114	03/03/1998	Thornfeldt, et al.	
	20	US-5744162	04/28/1998	Okabe, et al.	


[illegible]

Examiner Signature		Date Considered	4/25/02
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, this collection of information has been assigned the following OMB control number.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
and to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/703,753
Filing Date	November 1, 2000
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	S. Jiang
Attorney Docket Number	01736349

Sheet 2 of 21

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

[illegible]


**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/703,753
Filing Date	November 1, 2000
First Named Inventor	Robert E. Dudley
Art Unit	1617
Examiner Name	S. Jiang
Attorney Docket Number	01736349

Sheet **3** of **21****U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
S99	41	US-6251436	B1	06/26/2001	Drizen, et al.	
	42	US-6266560	B1	07/24/2001	Zhang, et al.	
	43	US-6267985	B1	07/31/2001	Chen, et al.	
	44	US-6277884	B1	08/21/2001	de Tejada	
	45	US-6294192	B1	09/25/2001	Patel, et al.	
	46	US-6294550	B1	09/25/2001	Place, et al.	
	47	US-6299900	B1	10/09/2001	Reed, et al.	
	48	US-6306841	B1	10/23/2001	Place, et al.	
	49	US-6323242	B1	11/27/2001	Mueller	
	50	US-6331543	B1	12/18/2001	Garvey, et al.	
S99	51	US-010018073	A1	08/30/2001	Dittgen, et al.	
	52	US-010023261	A1	09/20/2001	Ryoo, et al.	
	53	US-010033870	A1	10/25/2001	Luo, et al.	
	54	US-010036483	A1	11/01/2001	Luo, et al.	
	55	US-010051166	A1	12/13/2001	Luo, et al.	
	56	US-010051656	A1	12/13/2001	Place, et al.	
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)				
S99	57	WO	92/15289 A1	09/17/1992	Mantelle		
	58	WO	93/25168 A1	12/23/1993	Heiber, et al.		
	59	WO	94/21230 A1	09/29/1994	Elias, et al.		
	60	WO	94/28902 A1	12/22/1994	Ellis, et al.		
	61	WO	96/16644 A1	06/06/1996	Campbell, et al.		
	62	WO	96/16657 A1	06/06/1996	Cambell, et al.		
	63	WO	96/27372 A1	09/12/1996	Allen		
	64	WO	96/36339 A2	11/21/1996	Mantzoros		
	65	WO	97/03985 A1	02/06/1997	Daugan, et al.		
	66	WO	97/24148 A1	07/10/1997	Chen, et al.		

Examiner
Signature

S99

Date
Considered

4/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-01)




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature	<i>SAG</i>	Date Considered	<i>4/25/02</i>
-----------------------	------------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



RECEIVED

PTO/SB/088R(10/01) 2002
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
TEST CENTER 1000/2000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/703,753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
Sheet 6 of 21	Attorney Docket Number	01736349	


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAG	80	RINGHAM, ET AL., "Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel in Hypogonadal Men," Unimed Pharmaceuticals (October 31, 2000).	
	81	LONGSTRETH, ET AL., "Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment," Unimed Pharmaceuticals (October 31, 2000).	
	82	KAUFMAN, "Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation," International Journal of Impotence Research, Vol. 12 (Supplement 3), p. S75 (B9) (September 2000).	
	83	JORDAN, "Allergy and Topical Irritation Associated With Transdermal Testosterone Administration: A Comparison of Scrotal and Nonscrotal Transdermal Systems," American Journal of Contact Dermatitis, Vol. 8 (No. 2), pp. 108-113 (June 1997).	
	84	GOUCHIE, ET AL., "The Relationship Between Testosterone Levels and Cognitive Ability Patterns," Psychoneuroendocrinology, Vol. 16 (No. 4), pp. 323-334 (1991).	
	85	DOBS, ET AL., "Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 10), pp. 3469-3478 (1999).	
	86	PERSKY, ET AL., "Plasma Testosterone Level and Sexual Behavior of Couples," Archives of Sexual Behavior, Vol. 7 (No. 3), pp. 157-173 (May 1978).	
	87	AHMED, ET AL., "Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism," Journal Of Clinical Endocrinology And Metabolism, Vol. 66 (No. 3), pp. 546-551 (March 1988).	
	88	BALS-PRATSCH, ET AL., "Transdermal Testosterone Substitution Therapy for Male Hypogonadism," The Lancet, Vol. 2 (No. 8513), pp. 943-46 (October 25, 1986).	
	89	PLYMATE, ET AL., "Circadian Variation in Testosterone, Sex Hormone-Binding Globulin and Calculated Non-Sex Hormone-Binding Globulin Bound Testosterone in Healthy Young and Elderly Men," Journal of Andrology, Vol. 10 (No. 5), pp. 366-371 (September-October 1989).	
SAG	90	CUNNINGHAM, ET AL., "Testosterone Replacement with Transdermal Therapeutic Systems - Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels," JAMA, Vol. 261 (No. 17), pp. 2525-2530 (May 5, 1989).	

Examiner Signature		Date Considered	4/25/02
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED
PTO/SB/08B (10-01)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
APR 9 2002
CHIEF CENTER 1000/2000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 21

Complete if Known

Application Number	09/703,753
Filing Date	November 1, 2000
First Named Inventor	Robert E. Dudley
Group Art Unit	1617
Examiner Name	S. Jiang
Attorney Docket Number	01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJD	91	TENOVER, ET AL., "Age-Related Alterations in the Circadian Rhythms of Pulsatile Luteinizing Hormone and Testosterone Secretion in Healthy Men," Journal of Gerontology, Vol. 43 (No. 6), pp. M163-169 (November 1988).	
	92	CONWAY, ET AL., "Randomized Clinical Trial of Testosterone Replacement Therapy in Hypogonadal Men," International Journal Of Andrology, Vol. 11 (No. 4), pp. 247-264 (August 1988).	
	93	PLACE, ET AL., "Transdermal Delivery of Testosterone with Testoderm to Provide Normal Circadian Pattern of Testosterone," Annals New York Academy of Sciences, Vol. 618, pp. 441-449 (1991).	
	94	BHASIN, ET AL., "A Biodegradable Testosterone Microcapsule Formulation Provides Uniform Eugonadal Levels of Testosterone for 10-11 Weeks in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 1), pp. 75-83 (January 1992).	
	95	ARVER, ET AL., "Improvement of Sexual Function in Testosterone Deficient Men Treated for 1 Year with a Permeation Enhanced Testosterone Transdermal System," Journal Of Urology, Vol. 155 (No. 5), pp. 1604-1608 (May 1996).	
	96	LIAO, "Androgen Action: Molecular Mechanism and Medical Application," J. Formos Med. Assoc., Vol. 93 (No. 9), pp. 741-751 (September 1994).	
	97	CARLSTROM, ET AL., "Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function," International Journal Of Andrology (Vol. 13), pp. 67-73 (1990).	
	98	de LIGNIERES, ET AL., "Treatment of Male Hypogonadism by Topical Administration of Androgens," pp. 273-283 (1980).	
	99	DAVIDSON, ET AL., "Hormonal Changes and Sexual Function in Aging Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 57 (No. 1), pp. 71-77 (1983).	
	100	VERMEULEN, ET AL., "Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins," Maturitas, Vol. 7, pp. 281-287 (1985).	
SJD	101	MORRISON, "Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women," Psychopharmacology Bulletin, Vol. 33 (No. 2), pp. 293-296 (1997).	

Examiner Signature

SJD


Date Considered

4/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJG	102	JAFFE, ET AL., "Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men", Horm. Res., Vol. 41, pp. 215-217 (1994).	
	103	MORLEY, ET AL., "Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy," J. Lab. Clin. Med., Vol. 135 (No. 5), pp. 370-378 (May 2000).	
	104	MARIN, ET AL., "Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues," European Journal of Medicine, Vol. 1 (No. 6), pp. 329-336 (October 1992).	
	105	WANG, ET AL., "Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study," The Journal Of Endocrinology And Metabolism, Vol. 85 (No. 3), pp. 964-969 (March 2000).	
	106	KUHN, ET AL., "Percutaneous Androgen Treatment for Male Hypogonadism. Compared Efficacy of Testosterone and Dihydrotestosterone: Study of 40 Observations," Endocrinologie, Vol. 14 (No. 11), pp. 1031-1036 (1986) (English Translation).	
	107	HANDELSMAN, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Pellets in Man," Journal Of Clinical Endocrinology And Metabolism, Vol. 70 (No. 1), pp. 216-222 (1990).	
	108	STUENKEL, ET AL., "Sublingual Administration of Testosterone-Hydroxypropyl-b-Cyclodextrin Inclusion Complex Simulates Episodic Androgen Release in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 72 (No.5), pp. 1054-1059 (May 1991).	
	109	BHASIN, "Clinical Review 34 - Androgen Treatment of Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 6), pp. 1221-1225 (June 1992).	
	110	SALEHIAN, ET AL., "Pharmacokinetics, Bioefficacy, and Safety of Sublingual Testosterone Cyclodextrin in Hypogonadal Men: Comparison to Testosterone Enanthate - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 80 (No. 12), pp. 3567-3575 (1995).	
	111	MEIKLE, ET AL., "Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 5), pp. 1832-1840 (May 1996).	
SJG	112	WANG, ET AL., "Testosterone Replacement Therapy Improves Mood in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3578-3583 (1996).	

Examiner
Signature

SJG

Date


Considered

4/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/703,753
Sheet 9 of 21		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
		Attorney Docket Number	01736349


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJG	113	WANG, ET AL., "Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3654-3662 (1996).	
	114	McCLELLAN, ET AL., "Transdermal Testosterone," Drugs, Vol. 55 (No. 2), pp. 253-258 (February 1998).	
	115	BHASIN, ET AL., "Therapeutic Perspective - Issues in Testosterone Replacement in Older Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 10), pp. 3435-3448 (1998).	
	116	BEHRE, ET AL., "Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male Hypogonadism: Phase I Studies," European Journal Of Endocrinology, Vol. 140, pp. 414-419 (1999).	
	117	BEHRE, ET AL., "Long-Term Substitution Therapy of Hypogonadal Men with Transscrotal Testosterone Over 7-10 Years," Clinical Endocrinology, Vol. 50, pp. 629-635 (1999).	
	118	PARKER, ET AL., "Experience with Transdermal Testosterone Replacement Therapy for Hypogonadal Men," Clinical Endocrinology, Vol. 50, pp. 57-62 (1999).	
	119	SNYDER, ET AL., "Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 6), pp. 1966-1972 (1999).	
	120	WANG, ET AL., "Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 8), pp. 2749-2757 (August 1998).	
	121	LEIFKE, ET AL., "Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Vertebral Body Area and Paraspinal Muscle Area in Hypogonadal Men," European Journal of Endocrinology, Vol. 138, pp. 51-58 (1998).	
SJG	122	BEHRE, ET AL., "Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 82 (No. 8), pp. 2386-2390 (1997).	

Examiner Signature	<i>SJG</i>	Date Considered	4/25/02
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SPJ	123	DAMASSA, ET AL., "Sex Hormone-Binding Globulin and Male Sexual Development," Neuroscience And Biobehavioral Reviews, Vol. 19 (No. 2), pp. 165-175 (1995).	
	124	MORLEY, ET AL., "Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men," Metabolism, Vol. 46 (No. 4), pp. 410-413 (April 1997).	
	125	CUNNINGHAM, ET AL., "Plasma Sex Hormone-Binding Globulin Levels Decrease During the Second Decade of Life Irrespective of Pubertal Status," Journal Of Clinical Endocrinology And Metabolism, Vol. 58 (No. 5), pp. 915-918 (1984).	
	126	LEWIS, ET AL., "Serum 5a-Dihydrotestosterone and Testosterone Changes with Age in Man," ACTA Endocrinologica, Vol. 82, pp. 444-448 (1976).	
	127	HARDY, ET AL., "Endocrine Assessment of Impotence - Pitfalls of Measuring Serum Testosterone Without Sex-Hormone-Binding Globulin," Postgrad Medical Journal, Vol. 70, pp. 836-837 (1994).	
	128	DAVIDSON, ET AL., "Hormonal Replacement and Sexuality in Men," Clinics In Endocrinology And Metabolism, Vol. 11 (No. 3), pp. 599-623 (November 1982).	
	129	MANTZOROS, ET AL., "Contribution of Dihydrotestosterone to Male Sexual Behavior," British Medical Journal, Vol. 310, pp 1289-1291 (May 20, 1995).	
	130	MOORADIAN, ET AL., "Biological Actions of Androgens," Endocrine Reviews, Vol. 8 (No. 1), pp 1-28 (1987).	
	131	CUNNINGHAM, ET AL., "Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men," Journal Of Clinical Endocrinology and Metabolism, Vol. 70 (No. 3), pp. 792-797 (1990).	
	132	SKAKKEBAEK, ET AL., "Androgen Replacement with Oral Testosterone Undecanoate in Hypogonadal Men: A Double Blind Controlled Study," Clinical Endocrinology, Vol. 14, pp. 49-61 (1981).	
SPJ	133	de LIGNIERES, "Transdermal Dihydrotestosterone Treatment of Andropause," Annals Of Medicine, Vol. 25, pp. 235-241 (1993).	


Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJ	134	CHEMANA, ET AL., "Percutaneous Absorption of 5a-dihydrotestosterone in Man II. Percutaneous Administration of 5a-dihydrotestosterone in Hypogonadal Men with Idiopathic Haemochromatosis: Clinical, Metabolic and Hormonal Effectiveness," International Journal Of Andrology, Vol. 5, pp. 595-606 (1982).	
	135	McCLURE, ET AL., "Hypogonadal Impotence Treated by Transdermal Testosterone," Urology, Vol. XXXVII (No. 3), pp. 224-228 (March 1991).	
	136	GOOREN, "Androgen Levels and Sex Functions in Testosterone-Treated Hypogonadal Men," Archives Of Sexual Behavior, Vol. 16 (No. 6), pp. 463-473 (1987).	
	137	TSITOURAS, "Effects of Age on Testicular Function," Endocrinology And Metabolism Clinics, Vol. 16 (No. 4), pp.1045-1059 (December 1987).	
	138	ANDERSON, ET AL., "The Effects of Exogenous Testosterone on Sexuality and Mood of Normal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 75 (No. 6), pp.1503-1507 (1992).	
	139	KNUSSMANN, ET AL., "Relations Between Sex Hormone Levels and Sexual Behavior in Men," Archives Of Sexual Behavior, Vol. 15 (No.5), pp. 429-5 (1986).	
	140	BANCROFT, "Endocrinology of Sexual Function," Clinics In Obstetrics And Gynecology, Vol. 7 (No. 2), pp. 253-281 (August 1980).	
	141	BAGATELL, ET AL., "Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 78 (No. 3), pp. 711-716 (1994).	
	142	WEINBAUER, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate and Dihydrotestosterone Enanthate in Non-Human Primates," ACTA Endocrinologica (COPENH), Vol. 122 (No. 4), pp. 432-442 (1990).	
	143	"Sexual Dysfunction in the Male - Sexual Arousal Disorder," The Merck Manual, Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992).	
SJ	144	JOCKENHOVEL, ET AL., "Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men," Clinical Endocrinology, Vol. 45, pp. 61-71 (1996).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB/08B (10-01)

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAJ	145	BEHRE, ET AL., "Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester," Journal Of Endocrinology And Metabolism, Vol. 75 (No. 5), pp. 1204-1210 (1992).	
	146	SCHURMEYER, ET AL., "Comparative Pharmacokinetics of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men," International Journal of Andrology, Vol. 7, pp. 181-187 (1984).	
	147	MAZER, ET AL., "Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men," Journal of Controlled Release, Vol. 19, pp. 347-361 (1992).	
	148	COFRANCESCO, Jr., ET AL., "Transdermal Testosterone Delivery Systems," The Endocrinologist, Vol. 6 (No. 3), pp. 207-213 (1996).	
	149	BROCKS, ET AL., "Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose," Journal of Clinical Pharmacology, Vol. 36, pp. 732-739 (1996).	
	150	ARVER, ET AL., "Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men," Clinical Endocrinology, Vol. 47, pp. 727-737 (1997).	
	151	MEIKLE, ET AL., "Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 43, pp. 449-457 (1996 Wiley-Liss, Inc.).	
	152	BALS-PRATSCH, ET AL., "Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year," ACTA Endocrinologica (COPENH), Vol. 118, pp. 7-13 (1988).	
	153	CAREY, ET AL., "Transdermal Testosterone Treatment of Hypogonadal Men," The Journal of Urology, Vol. 140, pp. 76-79, (July 1988).	
SAJ	154	CUNNINGHAM, ET AL., "Testosterone Transdermal Delivery System," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 42, pp. 437-447 (1996 Wiley-Liss, Inc.).	
	155	Product Information - Testoderm-TTS, Physicians' Desk Reference, Alza pp. 517-520.	


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 21

Complete if Known

Application Number	09/703,753
Filing Date	November 1, 2000
First Named Inventor	Robert E. Dudley
Group Art Unit	1617
Examiner Name	S. Jiang
Attorney Docket Number	01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
590	156	YU, ET AL., "Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men," Journal of Clinical Pharmacology, Vol. 37, pp. 1139-1145 (1997).	
	157	YU, ET AL., "Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application," Journal of Clinical Pharmacology, Vol. 37, pp. 1129-1138 (1997).	
	158	WALTERS, "Penetration Enhancers and Their Use in Transdermal Therapeutic Systems," pp. 202-227 (1990).	
	159	GENNARO, "Remington: The Science and Practice of Pharmacy, 20th Edition," Chapter 44, pp. 842-843 (2000).	
	160	JARKANDER-ROLFF, ET AL., "Transdermal Application of A Testosterone Gel - A Pharmacokinetic Study."	
	161	TIRASSA, ET AL., "High-Dose Anabolic Androgenic Steroids Modulate Concentrations of Nerve Growth Factor and Expression of its Low Affinity Receptor (p75-NGFr) in Male Rat Brain," Journal of Neuroscience Research, Vol. 47 (No. 2), pp. 198-207 (January 15, 1997).	
	162	VELDHUIS, ET AL., "Muting of Androgen Negative Feedback Unveils Impoverished Gonadotropin-Releasing Hormone/Luteinizing Hormone Secretory Reactivity in Healthy Older Men," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No. 2), pp. 529-535. (2001)	
	163	MILLER, ET AL., "Androgen Deficiency in Women with Hypopituitarism," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No.2), pp. 561-567 (2001).	
	164	KAO, ET AL., "Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: in vitro Studies with Mouse Skin in Organ Culture," Journal of Pharmacology and Experimental Therapeutics, Vol. 241 (No. 2), pp. 482-487 (May 1987).	
	165	FINDLAY, ET AL., "Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 68 (No. 2), pp. 369-373 (February 1989).	
390	166	ERNESTI, ET AL., "Absorption and Metabolism of Topically Applied Testosterone in an Organotypic Skin Culture," Skin Pharmacology, Vol. 5 (No. 3), pp. 146-153 (1992).	

Examiner
Signature

Date


Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Approved for [] through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	167	CHOI, ET AL., "Transdermal Dihydrotestosterone Therapy and its Effects on Patients with Microphallus," Journal Of Urology, Vol. 150 (No. 2) (Part 2), pp. 657-660 (August 1993).	
	168	Testosterone, Chapters 1, 6-16 (1999).	
	169	TSAI, ET AL., "Metabolic Approaches to Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors." Journal of Pharmaceutical Sciences, Vol. 85 (No. 6), pp. 643-648 (June 1996).	
	170	MEIKLE, ET AL., "Familial Effects on Plasma Sex-Steroid Content in Man: Testosterone, Estradiol and Sex-Hormone-Binding Globulin." Metabolism. Vol. 31 (No. 1). pp. 6-9 (January 1982).	
	171	SHANBHAG, ET AL., "The Temperature Dependence of the Binding of 5 Alpha-Dihydrotestosterone, Testosterone and Estradiol to the Sex Hormone Globulin (SHBG) of Human Plasma," J. Steroid Biochem., Vol. 24 (No. 2), pp. 549-555 (February 1986).	
	172	BELGOROSKY, ET AL., "Changes in Serum Sex Hormone-Binding Globulin and in Serum Non-Sex Hormone-Binding Globulin-Bound Testosterone During Prepuberty in Boys," J. Steroid Biochem., Vol. 27 (Nos. 1-3), pp. 291-295 (1987).	
	173	KORENMAN, ET AL., "Androgen Therapy of Hypogonadal Men with Transscrotal Testosterone Systems," American Journal Of Medicine, Vol. 83 (No. 3), pp. 471-478 (September 1987).	
	174	MITCHELL, ET AL., "Age Related Changes in the Pituitary-Testicular Axis in Normal Men; Lower Serum Testosterone Results from Decreased Bioactive LH Drive," Clinical Endocrinology (OXF), Vol. 42 (No. 5), pp. 501-507 (May 1995).	
	175	NANKIN, ET AL., "Decreased Bioavailable Testosterone In Aging Normal and Impotent Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 6), pp. 1418-1420 (December 1986).	
	176	TENOVER, ET AL., "The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clomiphene Citrate," Journal Of Clinical Endocrinology And Metabolism, Vol. 65 (No. 6), pp. 1118-1126 (December 1987).	
[Signature]	177	WINTERS, ET AL., "The Gonadotropin-Suppressive Activity of Androgen is Increased in Elderly Men," Metabolism, Vol. 33 (No. 11), pp. 1052-1059 (November 1984).	

Examiner Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR 28 2002

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 15 of 21

Complete If Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAG	178	MEIKLE, ET AL., "Enhanced Transdermal Delivery of Testosterone Across Nonscrotal Skin Produces Physiological Concentrations of Testosterone and Its Metabolites in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 3), pp. 623-628 (March 1992).	
	179	WINTERS, ET AL., "Serum LH Concentrations in Hypogonadal Men During Transdermal Testosterone Replacement Through Scrotal Skin: Further Evidence That Ageing Enhances Testosterone Negative Feedback. The Testoderm Study Group," Clinical Endocrinology (OXF), Vol. 47 (No. 3), pp. 317-322 (September 1997).	
	180	BOYLE, ET AL., "Serum Testosterone Measurements," American Journal Of Clinical Pathology, Vol. 81 (No. 6), pp. 754-761 (June 1984).	
	181	HOLOWNIA, ET AL., "A Clinical Evaluation of A Direct Radioimmunoassay of Testosterone," Clinical Chimica Acta, Vol. 214 (No. 1), pp. 31-43 (January 31, 1993).	
	182	BELGOROSKY, ET AL., "Progressive Decrease in Serum Sex Hormone-Binding Globulin from Infancy to Late Puberty in Boys," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 2), pp. 510-512 (August 1986).	
	183	VALERO-POLITI, ET AL., "Daily Rhythmic and Non-Rhythmic Variations of Follitropin, Lutropin, Testosterone, and Sex-Hormone-Binding Globulin in Men," Eur. J. Clin. Chem. Clin. Biochem., Vol. 34 (No. 6), pp. 455-462 (June 1996).	
	184	VALERO-POLITI, ET AL., "Annual Rhythmic Variations of Follitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men," Clinica Chimica Acta, Vol. 271 (No. 1), pp. 57-71 (March 9, 1998).	
	185	LONGCOPE, ET AL., "Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 71 (No. 6), pp. 1442-1446 (December 1990).	
	186	BELGOROSKY, ET AL., "Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones," J. Steroid Biochem., Vol. 18 (No. 6), pp. 783-787 (June 1983).	
	187	LEWIS, ET AL., "Proceedings: Age-Related Changes in Serum Sapha-dihydrotestosterone and Testosterone in Normal Men," Journal Of Endocrinology, Vol. 67 (No. 2), pp. 15P (November 1975).	
SAG	188	PIRKE, ET AL., "Age Related Changes and Interrelationships Between Plasma Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males," ACTA Endocrinologica (COPENH), Vol. 74 (No. 4), pp. 792-800 (December 1973).	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0034
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 16 of 21

Complete if Known

Application Number	09/703,753
Filing Date	November 1, 2000
First Named Inventor	Robert E. Dudley
Group Art Unit	1617
Examiner Name	S. Jiang
Attorney Docket Number	01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJG	189	MASTERS, ET AL., "Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol," Clinical Chemistry, Vol. 35 (No. 6), pp. 979-984 (June 1989).	
	190	WANG, ET AL., "Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 53 (No. 5), pp. 1021-1024 (November 1981).	
	191	ZMUDA, ET AL., "Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men," Metabolism, Vol. 45 (No. 8), pp. 935-939 (August 1996).	
	192	GAIDANO, ET AL., "Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty," Clinical Chimica Acta, Vol. 100 (No. 2), pp. 91-97 (January 15, 1980).	
	193	Definition of Isopropyl Myristate (5103), The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals, Eleventh Edition, p. 821 (1989).	
	194	GENNARO, ET AL., Remington's Pharmaceutical Sciences, Eighteenth Edition, pp. 1305, 1314-1315 (1990).	
	195	LANGTRY, ET AL., "Sildenafil - A Review of its Use in Erectile Dysfunction," Drugs, Vol. 57 (No. 6), pp. 967-989 (1999).	
	196	MORELAND, ET AL., "Sildenafil, A Novel Inhibitor of Phosphodiesterase Type 5 In Human Corpus Cavernosum Smooth Muscle Cells," Life Sciences, Vol. 62 (No. 20) pp. PL309-318 (1998).	
	197	FAHRNER, ET AL., "Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG)," International Journal Of Sports Medicine, Vol. 19 (No. 1), pp. 12-15 (January 1998). [Abstract]	
	198	BARTSCH, "Interrelationships Between Sex Hormone-Binding Globulin and Testosterone, 5 alpha-Dihydrotestosterone and Oestradiol-17 beta in Blood of Normal Men," Maturitas, Vol. 2 (No. 2), pp. 109-118 (July 1980). [Abstract]	
SJG	199	WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," Clinical Endocrinology, Vol. 54, pp. 1-13 (2001).	

Examiner
Signature

Date


Considered

4/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 17 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SAJ	200	GOOREN, "A Ten-Year Safety Study of the Oral Androgen Testosterone Undecanoate," J. Androl., Vol. 15 (No. 3), pp. 212-215 (May-June 1994). [Abstract]	
	201	MAZER, "New Clinical Applications of Transdermal Testosterone Delivery in Men and Women," J. Controlled Release, Vol. 65 (No. 1-2), pp. 303-315 (March 1, 2000). [Abstract]	
	202	ITOH, ET AL., "The Assessment of Bioavailable Androgen Levels from the Serum Free Testosterone Level," Nippon Naibunpi Gakkai Zasshi, Vol. 67 (No. 1), pp. 23-32 (January 20, 1991). [Abstract]	
	203	Male Hormone Patch Approved, Nupharm, http://www.nupharm.com/malehorm.htm .	
	204	"SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available," International Association of Physicians in AIDS Care, http://www.iapac.org/clinmgt/compnews/sb061297.html (June 12, 1997).	
	205	"Impotence Treatments," Impotence World Association, http://www.impotenceworld.org/treatment.htm (2000).	
	206	"Andro Gel," Netrition, http://www.netrition.com/andro_gel_page.html (1997-1998).	
	207	"Cellegy Pharmaceuticals Market Opportunities," CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market.html (1997).	
	208	"Prospectus - Cellegy Pharmaceuticals, Inc.," OPPENHEIMER & CO., pp. 1-4, 21-28 (1997).	
	209	The Testosterone Source, http://www.testosteronesource.com (1998).	
SAJ	210	BONNEY, "Hormone Replacement Therapy for Men," American Clinical Laboratory, http://iscpubs.com/pubs/acl/acl1197.html (November/December 1997).	

Examiner
Signature

SAJ


Date
Considered

4/28/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/703.753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
		Attorney Docket Number	01736349
Sheet	18	of	21

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	211	Andropausal, Los Gatos Longevity Institute, http://www.antiaging.com/andropause.html (1998).	
	212	TestoCreme - A Natural Transdermal Testosterone Replacement Therapy, www.testocrema.com .	
SJD	213	WANG, ET AL., "Pharmacokinetics Of Transdermal Testosterone Gel in Hypogonadal Men," ENDO '98 SUBMISSION PROGRAM, 1998N ABSTRACT FORM.	
	214	SWERDLOFF, ETAL., "Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men," 2347 Male Reproductive Poster Session, Board 578 (June 22, 2000).	
	215	WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," 2348 Male Reproductive Poster Session, Board 579 (June 22, 2000).	
	216	WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," Basic Science: Reproduction-Gonadal Control (Male), Male Reproduction Oral Session, No. 1360 (June 24, 2000).	
	217	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www.FNGHD.com (August 19, 1998).	
SJD	218	RIGGS, "Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel," Unimed News Release, pp. 1-2 (March 31, 1997).	
	219	Androgel-1% (testosterone gel) CIII.; www.Androgel.com , pp. 1-2.	
SJD	220	VERGEL, "Anabolic Steroids: A Practical Guide," CRIA Update, Vol. 7 (No. 3) (Summer 1998).	
	221	MOONEY, "Frequency of Administration - Testosterone & Nandrolone," Vol. 1 (No. 4); www.mediabolics.com (Downloaded-10/8/98).	

Examiner Signature	<i>SJD</i>	Date Considered	4/25/02
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 19 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SD	222	Anabolic Steroids, Project Inform, Anabolic Steroids Quick Sheet (December 1997).	
SD	223	"Anabolic Steroid Boosts Weight," GMHC Treatment Issues, Vol. 10, No. 9 (September 1996).	
	224	Anabolic Steroids, Project Inform Hotline Handout, www.projinf.org. (Downloaded-10/8/98).	
	225	Anabolic Steroids - A Simple Facts Sheet From The Network, www.network/simple/steroids (Downloaded 10/27/98).	
	226	USP Drug Information - Anabolic Steroids (Systemic), MayoClinic, www.mayohealth.org (Downloaded-10/8/98).	
SD	227	MOONEY, "Anabolic Steroids For AIDS Therapy: Differences Between Analogs," No. 1, www.digiweb.com. (July 1998).	
	228	Testocrema - No Shots, No Pills, No Patches, www.testocrema.com (Downloaded-7/10/00).	
SD	229	"ENDO 99: Testosterone Patch Effective For Diminished Sexual Function in Surgically Menopausal Women," www.pslgroup.com (June 15, 1999).	
SD	230	"Data Supports Safety of Estratest For Men," Doctor's Guide, www.pslgroup.com (March 9, 1998).	
SD	231	"Testosterone's Role in the Female Sex Drive," USA Today News, www.usatoday.com (April 8, 1996).	
	232	"Alternative to Viagra For Women?," www.mdhealthline.com (Downloaded-8/7/00).	

Examiner
Signature

SD

Date
Considered

4/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	20	of	21
-------	----	----	----

Complete If Known	
Application Number	09/703,753
Filing Date	November 1, 2000
First Named Inventor	Robert E. Dudley
Group Art Unit	1617
Examiner Name	S. Jiang
Attorney Docket Number	01736349

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SSD	233	"Never Too Buff," Time Europe, www.time.com, Vol. 155 (No. 16) (April 24, 2000).	
	234	Géfael, Graeme's Testosterone Page, www.voyager.co.nz (5/12/00).	
	235	Estrogel, www.netdoktor.dk/medicin/Fakta/Estrogel (Downloaded 6/26/01).	
	236	La Sexualite . . . , L'Androgel, Le Gel Miracle, www.aci-multimedia.net/feminin/androgel (Downloaded 5/9/01).	
	237	Stehli, et al., Info . . . , Info . . . , Info . . . - Androgel, www.mageos:ifrance.com/nade38/androgel (Downloaded 5/9/01).	
	238	CHERRIER, ET AL., "T-Gel Study: Cognitive Effects of Exogenous Testosterone Manipulation in Hypogonadal Men" (6/7/99).	
	239	"Bentley Pharmaceuticals Annouces Research and Licensing Agreements For Intranasal Pain Management and Topical Hormone Replacement Therapy," www.bentleypharm.com (downloaded 11/17/01).	
	240	"Testosterone Gel May Help Men with Low Sex Drive," WRAL ONLINE, http://www.wral-tv.com/features/healthteam/1997/08-14-tgel/ (August 14, 1997).	
	241	"Testocrema Transdermal Testosterone Is New," Preventive Medicine Clinic Of Monterey, http://www.wellnessmd.com/testo.html.	
	242	"SEPA Testosterone Transdermal Gel Receives Application by FDA," Doctor's Guide Global Edition, http://pslgroup.com/dg/123aa.htm (January 15, 1997).	
	243	Press Release - 10/21/99 - MacroChem Awarded U.S. Patent Covering Transdermal Hormone Replacement Incorporating Proprietary SEPA Technology and Hormonally Active Drugs Such as Testosterone, Estradiol and Progesterone, http://www.mchm.com/press/pr24.asp (October 21, 1999).	

Examiner Signature		Date Considered	4/25/02
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR 28 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 21 of 21

Complete If Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736615

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	244	AndrosteDERM, http://www.gethuge.net/androderm1.htm .	
	245	MANOS, "FDA Approves Gel to Treat Low Testosterone Levels," www.testocrema.com (Downloaded 5/09/01).	
	246	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www.INCIID.com (August 19, 1998).	
SJO	247	LACAYO, "Are You Man Enough?," Time Europe, www.Time.com , Vol. 155, No. 16 (April 24, 2000).	
	248	"MacroChem Accelerates Development of Top For Impotence," www.pslgroup.com (April 10, 1997).	
SJO	249	BRADLEY, "Potential Expanded Indications for Androgen Treatment," The Endocrine Society, No. 166 (ENDO 2000).	
	250	WANG, ET AL., "New Androgen Formulations," The Endocrine Society, No. 167 (ENDO 2000).	
	251	WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," The Endocrine Society, No. 1360 (ENDO 2000).	
	252	WITTERT, ET AL., "Androgen Deficiency in Aging Men," The Endocrine Society, No. 1626 (ENDO 2000).	
SJO	253	BRILL, ET AL., "Single and Joint Impact of One-Month of Transdermal Testosterone (T) and/or Recombinant Human Growth Hormone (rhGH) Supplementation on Body Composition, Strength, Balance, Function and Muscle IGF-I and Androgen Gene Expression in Healthy Older Men: A Prospective Randomized Double-Blind Crossover," The Endocrine Society, No. 1647 (ENDO 2000).	

Examiner Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. \

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

16

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/703.753		
		Filing Date	November 1, 2000		
		First Named Inventor	Robert E. Dudley		
		Art Unit	1617		
		Examiner Name	S. Jiang		
Sheet	1	of	21	Attorney Docket Number	01736349

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
SJD	1	US-4496556	01/29/1985	Orentreich	
	2	US-4695465	09/22/1987	Kigasawa, et al.	
	3	US-4863970	09/05/1989	Patel, et al.	
	4	US-4946870	08/07/1990	Partain, et al.	
	5	US-5053227	10/01/1991	Chiang, et al.	
	6	US-5059603	10/22/1991	Rubin	
	7	US-5152997	10/06/1992	Ebert, et al.	
	8	US-5256652	10/26/1993	El-Rashidy	
	9	US-5324521	06/28/1994	Gertner, et al.	
	10	US-5332577	07/26/1994	Gertner, et al.	
	11	US-5340586	08/23/1994	Pike, et al.	
	12	US-5346901	09/13/1994	Bell, et al.	
	13	US-5362497	11/08/1994	Yamada, et al.	
	14	US-5413794	05/09/1995	Suzuki, et al.	
	15	US-5460820	10/24/1995	Ebert, et al.	
	16	US-5550107	08/27/1996	Labrie	
	17	US-5648350	07/15/1997	De Lignieres	
	18	US-5719197	02/17/1998	Kanios, et al.	
	19	US-5723114	03/03/1998	Thornfeldt, et al.	
	20	US-5744162	04/28/1998	Okabe, et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			

Examiner Signature		Date Considered	5/24/02
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

U.S. Patent and Trademark Office: U.S. DÉPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/703.753
				Filing Date	November 1, 2000
				First Named Inventor	Robert E. Dudley
				Art Unit	1617
				Examiner Name	S. Jiang
Sheet	2	of	21	Attorney Docket Number	01736349

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
SAC	21	US-5785991	07/28/1998	Burkoth, et al.	
	22	US-5788983	08/04/1998	Chien, et al.	
	23	US-5855905	01/05/1999	Oettel, et al.	
	24	US-5877216	03/02/1999	Place, et al.	
	25	US-5932227	08/03/1999	Higo, et al.	
	26	US-5955455	09/21/1999	Labrie	
	27	US-6010716	01/04/2000	Saunal, et al.	
	28	US-6036977	03/14/2000	Drizen, et al.	
	29	US-6037346	03/14/2000	Doherty, et al.	
	30	US-6075028	06/13/2000	Graham	
	31	US-6077841	06/20/2000	Sui, et al.	
	32	US-6087362	07/11/2000	El-Rashidy	
	33	US-6087368	07/11/2000	Macor, et al.	
	34	US-6103765	08/15/2000	Neal	
	35	US-6124461	09/26/2000	Shoemaker	
	36	US-6127363	10/03/2000	Doherty, et al.	
	37	US-6139873	10/31/2000	Hughes, Jr., et al.	
	38	US-6156753	12/05/2000	Doherty, et al.	
	39	US-6238284 B1	05/29/2001	Dittgen, et al.	
	40	US-6248363 B1	06/19/2001	Patel, et al.	

APR 6 2002
 TECH CENTER 1600/2900

[illegible]

Examiner Signature	<i>SAJ</i>	Date Considered	5/21/02
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Turnaround Time: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/703.753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Art Unit	1617
		Examiner Name	S. Jiang
		Attorney Docket Number	01736349
Sheet	3	of	21

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SJG	41	US-6251436 B1	06/26/2001	Drizen, et al.	
	42	US-6266560 B1	07/24/2001	Zhang, et al.	
	43	US-6267985 B1	07/31/2001	Chen, et al.	
	44	US-6277884 B1	08/21/2001	de Tejada	
	45	US-6294192 B1	09/25/2001	Patel, et al.	
	46	US-6294550 B1	09/25/2001	Place, et al.	
	47	US-6299900 B1	10/09/2001	Reed, et al.	
	48	US-6306841 B1	10/23/2001	Place, et al.	
	49	US-6323242 B1	11/27/2001	Mueller	
	50	US-6331543 B1	12/18/2001	Garvey, et al.	
	51	US-010018073 A1	08/30/2001	Dittgen, et al.	
	52	US-010023261 A1	09/20/2001	Ryoo, et al.	
	53	US-010033870 A1	10/25/2001	Luo, et al.	
	54	US-010036483 A1	11/01/2001	Luo, et al.	
SJG	55	US-010051166 A1	12/13/2001	Luo, et al.	
	56	US-010051656 A1	12/13/2001	Place, et al.	
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SJG	57	WO 92/15289 A1	09/17/1992	Mantelle	
	58	WO 93/25168 A1	12/23/1993	Heiber, et al.	
	59	WO 94/21230 A1	09/29/1994	Elias, et al.	
	60	WO 94/28902 A1	12/22/1994	Ellis, et al.	
	61	WO 96/16644 A1	06/06/1996	Campbell, et al.	
	62	WO 96/16657 A1	06/06/1996	Cambell, et al.	
	63	WO 96/27372 A1	09/12/1996	Allen	
	64	WO 96/36339 A2	11/21/1996	Mantzoros	
	65	WO 97/03985 A1	02/06/1997	Daugan, et al.	
SJG	66	WO 97/24148 A1	07/10/1997	Chen, et al.	

Examiner Signature	Date Considered
SJG	5/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/703,753
				Filing Date	November 1, 2000
				First Named Inventor	Robert E. Dudley
				Art Unit	1617
				Examiner Name	S. Jiang
				Attorney Docket Number	01736349
Sheet	4	of	21		

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code 3	-Number ⁴ -Kind Code ⁵ (if known)				
SAJ	67	WO	97/43989 A1	11/27/1997	Portman, et al.		
	68	WO	98/34621 A1	08/13/1998	Rako		
	69	WO	99/24041 A1	05/20/1999	Mak, et al.		
	70	WO	99/66870 A1	12/29/1999	Fotinos		
	71	WO	00/45795 A2	08/10/2000	Lulla, et al.		
	72	WO	00/76522 A1	12/21/2000	Rosario-Jansen, et al.		
	73	WO	01/52823 A2	07/26/2001	Kanios		
	74	WO	01/76608 A1	10/18/2001	Lipp, et al.		
	75	EP	0196769 A2	10/08/1996	Chien, et al.		
	76	EP	0483105 B2	04/29/1992	Clearv		

Examiner Signature	<i>SAC</i>	Date Considered	<i>5/21/2002</i>
--------------------	------------	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/703.753
				Filing Date	November 1, 2000
				First Named Inventor	Robert E. Dudley
				Art Unit	1617
				Examiner Name	S. Jiang
Sheet	5	of	21	Attorney Docket Number	01736349

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
SRJ	77	EP 0491076 A1	06/24/1992	Patel, et al.	
	78	EP 0513832 A1	11/19/1992	Parab	
SRJ	79	EP 0581587 A2	02/02/1994	Kobayashi, et al.	

Examiner Signature	<i>SRJ</i>	Date Considered	5/21/02
-----------------------	------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> Sheet <u>6</u> of <u>21</u>		Complete if Known Application Number <u>09/703,753</u> Filing Date <u>November 1, 2000</u> First Named Inventor <u>Robert E. Dudley</u> Group Art Unit <u>1617</u> Examiner Name <u>S. Jiang</u> Attorney Docket Number <u>01736349</u>	
--	--	--	--

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAG	80	RINGHAM, ET AL., "Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel in Hypogonadal Men," Unimed Pharmaceuticals (October 31, 2000).	TECH CENTER 1000/2900
	81	LONGSTRETH, ET AL., "Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment," Unimed Pharmaceuticals (October 31, 2000).	
	82	KAUFMAN, "Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation," International Journal of Impotence Research," Vol. 12 (Supplement 3), p. S75 (B9) (September 2000).	
	83	JORDAN, "Allergy and Topical Irritation Associated With Transdermal Testosterone Administration: A Comparison of Scrotal and Nonscrotal Transdermal Systems," American Journal of Contact Dermatitis, Vol. 8 (No. 2), pp. 108-113 (June 1997).	
	84	GOUCHIE, ET AL., "The Relationship Between Testosterone Levels and Cognitive Ability Patterns," Psychoneuroendocrinology, Vol. 16 (No. 4), pp. 323-334 (1991).	
	85	DOBS, ET AL., "Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 10), pp. 3469-3478 (1999).	
	86	PERSKY, ET AL., "Plasma Testosterone Level and Sexual Behavior of Couples," Archives of Sexual Behavior, Vol. 7 (No. 3), pp. 157-173 (May 1978).	
	87	AHMED, ET AL., "Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism," Journal Of Clinical Endocrinology And Metabolism, Vol. 66 (No. 3), pp. 546-551 (March 1988).	
	88	BALS-PRATSCH, ET AL., "Transdermal Testosterone Substitution Therapy for Male Hypogonadism," The Lancet, Vol. 2 (No. 8513), pp. 943-46 (October 25, 1986).	
	89	PLYMATE, ET AL., "Circadian Variation in Testosterone, Sex Hormone-Binding Globulin and Calculated Non-Sex Hormone-Binding Globulin Bound Testosterone in Healthy Young and Elderly Men," Journal of Andrology, Vol. 10 (No. 5), pp. 366-371 (September-October 1989).	
SAG	90	CUNNINGHAM, ET AL., "Testosterone Replacement with Transdermal Therapeutic Systems - Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels," JAMA, Vol. 261 (No. 17), pp. 2525-2530 (May 5, 1989).	

Examiner Signature <u>SAG</u>	Date Considered <u>5/24/02</u>
-------------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 16 2002
RECEIVED
APR 16 2002

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAG	91	TENOVER, ET AL., "Age-Related Alterations in the Circadian Rhythms of Pulsatile Luteinizing Hormone and Testosterone Secretion in Healthy Men," Journal of Gerontology, Vol. 43 (No. 6), pp. M163-169 (November 1988).	
	92	CONWAY, ET AL., "Randomized Clinical Trial of Testosterone Replacement Therapy in Hypogonadal Men," International Journal Of Andrology, Vol. 11 (No. 4), pp. 247-264 (August 1988).	
	93	PLACE, ET AL., "Transdermal Delivery of Testosterone with Testoderm to Provide Normal Circadian Pattern of Testosterone," Annals New York Academy of Sciences, Vol. 618, pp. 441-449 (1991).	
	94	BHASIN, ET AL., "A Biodegradable Testosterone Microcapsule Formulation Provides Uniform Eugonadal Levels of Testosterone for 10-11 Weeks in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 1), pp. 75-83 (January 1992).	
	95	ARVER, ET AL., "Improvement of Sexual Function in Testosterone Deficient Men Treated for 1-Year with Permeation Enhanced Testosterone Transdermal System," Journal Of Urology, Vol. 155 (No. 5), pp. 1604-1608 (May 1996).	
	96	LIAO, "Androgen Action: Molecular Mechanism and Medical Application," J Formos Med. Assoc., Vol. 93 (No. 9), pp. 741-751 (September 1994).	
	97	CARLSTROM, ET AL., "Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function," International Journal Of Andrology (Vol. 13), pp. 67-73 (1990).	
	98	de LIGNIERES, ET AL., "Treatment of Male Hypogonadism by Topical Administration of Androgens," pp. 273-283 (1980).	
	99	DAVIDSON, ET AL., "Hormonal Changes and Sexual Function in Aging Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 57 (No. 1), pp. 71-77 (1983).	
	100	VERMEULEN, ET AL., "Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins," Maturitas, Vol. 7, pp. 281-287 (1985).	
SAG	101	MORRISON, "Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women," Psychopharmacology Bulletin, Vol. 33 (No. 2), pp. 293-296 (1997).	

Examiner
Signature

SAG

Date
Considered

5/24/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/703.753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
		Attorney Docket Number	01736349
Sheet	8	of	21

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAD	102	JAFFE, ET AL., "Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men", Horm. Res., Vol. 41, pp. 215-217 (1994).	
	103	MORLEY, ET AL., "Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy," J. Lab. Clin. Med., Vol. 135 (No. 5), pp. 370-378 (May 2000).	
	104	MARIN, ET AL., "Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues," European Journal of Medicine, Vol. 1 (No. 6), pp. 329-336 (October 1992).	
	105	WANG, ET AL., "Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study," The Journal Of Endocrinology And Metabolism, Vol. 85 (No. 3), pp. 964-969 (March 2000).	
	106	KUHN, ET AL., "Percutaneous Androgen Treatment for Male Hypogonadism: Compared Efficacy of Testosterone and Dihydrotestosterone: Study of 40 Observations," Endocrinologie, Vol. 14 (No. 11), pp. 1031-1036 (1986) (English Translation).	
	107	HANDELSMAN, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Pellets in Man," Journal Of Clinical Endocrinology And Metabolism, Vol. 70 (No. 1), pp. 216-222 (1990).	
	108	STUENKEL, ET AL., "Sublingual Administration of Testosterone-Hydroxypropyl-b-Cyclodextrin Inclusion Complex Simulates Episodic Androgen Release in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 72 (No.5), pp. 1054-1059 (May 1991).	
	109	BHASIN, "Clinical Review 34 - Androgen Treatment of Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 6), pp. 1221-1225 (June 1992).	
	110	SALEHIAN, ET AL., "Pharmacokinetics, Bioefficacy, and Safety of Sublingual Testosterone Cyclodextrin in Hypogonadal Men: Comparison to Testosterone Enanthate - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 80 (No. 12), pp. 3567-3575 (1995).	
	111	MEIKLE, ET AL., "Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 5), pp. 1832-1840 (May 1996).	
SAD	112	WANG, ET AL., "Testosterone Replacement Therapy Improves Mood in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3578-3583 (1996).	

Examiner Signature	SAD	Date Considered	5/24/02
--------------------	-----	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/703,753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
Sheet 9 of 21	Attorney Docket Number	01736349	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAG	113	WANG, ET AL., "Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3654-3662 (1996).	TECH CENTER 1600/2900
	114	McCLELLAN, ET AL., "Transdermal Testosterone," Drugs, Vol. 55 (No. 2), pp. 253-258 (February 1998).	
	115	BHASIN, ET AL., "Therapeutic Perspective - Issues in Testosterone Replacement in Older Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 10), pp. 3435-3448 (1998).	
	116	BEHRE, ET AL., "Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male Hypogonadism: Phase I Studies," European Journal Of Endocrinology, Vol. 140, pp. 414-419 (1999).	
	117	BEHRE, ET AL., "Long-Term Substitution Therapy of Hypogonadal Men with Transscrotal Testosterone Over 7-10 Years," Clinical Endocrinology, Vol. 50, pp. 629-635 (1999).	
	118	PARKER, ET AL., "Experience with Transdermal Testosterone Replacement Therapy for Hypogonadal Men," Clinical Endocrinology, Vol. 50, pp. 57-62 (1999).	
	119	SNYDER, ET AL., "Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 6), pp. 1966-1972 (1999).	
	120	WANG, ET AL., "Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 8), pp. 2749-2757 (August 1998).	
	121	LEIFKE, ET AL., "Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Vertebral Body Area and Paraspinal Muscle Area in Hypogonadal Men," European Journal of Endocrinology, Vol. 138, pp. 51-58 (1998).	
	122	BEHRE, ET AL., "Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 82 (No. 8), pp. 2386-2390 (1997).	

Examiner Signature	<i>SAG</i>	Date Considered	5/24/02
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/703,753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
Sheet 10 of 21	Attorney Docket Number	01736349	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SA	123	DAMASSA, ET AL., "Sex Hormone-Binding Globulin and Male Sexual Development," Neuroscience And Biobehavioral Reviews, Vol. 19 (No. 2), pp. 165-175 (1995).	
	124	MORLEY, ET AL., "Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men," Metabolism, Vol. 46 (No. 4), pp. 410-413 (April 1997).	
	125	CUNNINGHAM, ET AL., "Plasma Sex Hormone-Binding Globulin Levels Decrease During the Second Decade of Life Irrespective of Pubertal Status," Journal Of Clinical Endocrinology And Metabolism, Vol. 58 (No. 5), pp. 915-918 (1984).	
	126	LEWIS, ET AL., "Serum 5a-Dihydrotestosterone and Testosterone Changes with Age in Man," ACTA Endocrinologica, Vol. 82, pp. 444-448 (1976).	
	127	HARDY, ET AL., "Endocrine Assessment of Impotence - Pitfalls of Measuring Serum Testosterone Without Sex-Hormone-Binding Globulin," Postgrad Medical Journal, Vol. 70, pp. 836-837 (1994).	
	128	DAVIDSON, ET AL., "Hormonal Replacement and Sexuality in Men," Clinics In Endocrinology And Metabolism, Vol. 11 (No. 3), pp. 599-623 (November 1982).	
	129	MANTZOROS, ET AL., "Contribution of Dihydrotestosterone to Male Sexual Behavior," British Medical Journal, Vol. 310, pp 1289-1291 (May 20, 1995).	
	130	MOORADIAN, ET AL., "Biological Actions of Androgens," Endocrine Reviews, Vol. 8 (No. 1), pp 1-28 (1987).	
	131	CUNNINGHAM, ET AL., "Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men," Journal Of Clinical Endocrinology and Metabolism, Vol. 70 (No. 3), pp. 792-797 (1990).	
	132	SKAKKEBAEK, ET AL., "Androgen Replacement with Oral Testosterone Undecanoate in Hypogonadal Men: A Double Blind Controlled Study," Clinica Endocrinology, Vol. 14, pp. 49-61 (1981).	
SA	133	de LIGNIERES, "Transdermal Dihydrotestosterone Treatment of Andropause," Annals Of Medicine, Vol. 25, pp. 235-241 (1993).	

Examiner Signature		Date Considered	5/24/02
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 16 2002

RECEIVED
APR 16 2002

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/703,753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
Sheet 11 of 21	Attorney Docket Number	01736349	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJD	134	CHEMANA, ET AL., "Percutaneous Absorption of 5a-dihydrotestosterone in Man II. Percutaneous Administration of 5a-dihydrotestosterone in Hypogonadal Men with Idiopathic Haemochromatosis: Clinical, Metabolic and Hormonal Effectiveness," International Journal Of Andrology, Vol. 5, pp. 595-606 (1982).	
	135	McCLURE, ET AL., "Hypogonadal Impotence Treated by Transdermal Testosterone," Urology, Vol. XXXVII (No. 3), pp. 224-228 (March 1991).	
	136	GOOREN, "Androgen Levels and Sex Functions in Testosterone-Treated Hypogonadal Men," Archives Of Sexual Behavior, Vol. 16 (No. 6), pp. 463-473 (1987).	
	137	TSITOURAS, "Effects of Age on Testicular Function," Endocrinology And Metabolism Clinics, Vol. 16 (No. 4), pp.1045-1059 (December 1987).	
	138	ANDERSON, ET AL., "The Effects of Exogenous Testosterone on Sexuality and Mood of Normal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 75 (No. 6), pp.1503-1507 (1992).	
	139	KNUSSMANN, ET AL., "Relations Between Sex Hormone Levels and Sexual Behavior in Men," Archives Of Sexual Behavior, Vol. 15 (No.5), pp. 429-5 (1986).	
	140	BANCROFT, "Endocrinology of Sexual Function," Clinics In Obstetrics And Gynecology, Vol. 7 (No. 2), pp. 253-281 (August 1980).	
	141	BAGATELL, ET AL., "Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 78 (No. 3), pp. 711-716 (1994).	
	142	WEINBAUER, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate and Dihydrotestosterone Enanthate in Non-Human Primates," ACTA Endocrinologica (COPENH), Vol. 122 (No. 4), pp. 432-442 (1990).	
	143	"Sexual Dysfunction in the Male - Sexual Arousal Disorder," The Merck Manual, Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992).	
SJD	144	JOCKENHOVEL, ET AL., "Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men," Clinical Endocrinology, Vol. 45, pp. 61-71 (1996).	

Examiner Signature	<i>SJD</i>	Date Considered	5/24/02
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

APR 16 2002

TECHCENTER 1600/2900

TECHCENTER 1600/2900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAJ	145	BEHRE, ET AL., "Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester," Journal Of Endocrinology And Metabolism, Vol. 75 (No. 5), pp. 1204-1210 (1992).	
	146	SCHURMEYER, ET AL., "Comparative Pharmacokinetics of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men," International Journal of Andrology, Vol. 7, pp. 181-187 (1984).	
	147	MAZER, ET AL., "Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men," Journal of Controlled Release, Vol. 19, pp. 347-361 (1992).	
	148	COFRANCESCO, Jr., ET AL., "Transdermal Testosterone Delivery System," The Endocrinologist, Vol. 6 (No. 3), pp. 207-213 (1996).	
	149	BROCKS, ET AL., "Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose," Journal of Clinical Pharmacology, Vol. 36, pp. 732-739 (1996).	
	150	ARVER, ET AL., "Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men," Clinical Endocrinology, Vol. 47, pp. 727-737 (1997).	
	151	MEIKLE, ET AL., "Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 43, pp. 449-457 (1996 Wiley-Liss, Inc.).	
	152	BALS-PRATSCH, ET AL., "Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year," ACTA Endocrinologica (COPENH), Vol. 118, pp. 7-13 (1988).	
	153	CAREY, ET AL., "Transdermal Testosterone Treatment of Hypogonadal Men," The Journal of Urology, Vol. 140, pp. 76-79, (July 1988).	
	154	CUNNINGHAM, ET AL., "Testosterone Transdermal Delivery System," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 42, pp. 437-447 (1996 Wiley-Liss, Inc.).	
SAJ	155	Product Information - Testoderm TTS, Physicians' Desk Reference, Alza pp 517-520.	

Examiner Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 21

Complete if Known

Application Number 09/703,753
 Filing Date November 1, 2000
 First Named Inventor Robert E. Dudley
 Group Art Unit 1617
 Examiner Name S. Jiang
 Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAJ	156	YU, ET AL., "Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men," Journal of Clinical Pharmacology, Vol. 37, pp. 1139-1145 (1997).	
	157	YU, ET AL., "Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application," Journal of Clinical Pharmacology, Vol. 37, pp. 1129-1138 (1997).	
	158	WALTERS, "Penetration Enhancers and Their Use in Transdermal Therapeutic Systems," pp. 202-227 (1990).	
	159	GENNARO, "Remington: The Science and Practice of Pharmacy, 20th Edition Chapter 44, pp. 842-843 (2000).	
	160	JARKANDER-ROLFF, ET AL., "Transdermal Application of A Testosterone Gel - A Pharmacokinetic Study."	
	161	TIRASSA, ET AL., "High-Dose Anabolic Androgenic Steroids Modulate Concentrations of Ne Growth Factor and Expression of its Low Affinity Receptor (p75-NGFr) in Male Rat Brain," Journal of Neuroscience Research, Vol. 47 (No. 2), pp. 198-207 (January 15, 1997).	
	162	VELDHUIS, ET AL., "Muting of Androgen Negative Feedback Unveils Impoverished Gonadotropin-Releasing Hormone/Luteinizing Hormone Secretory Reactivity in Healthy Older Men," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No. 2), pp. 529-535. (2001)	
	163	MILLER, ET AL., "Androgen Deficiency in Women with Hypopituitarism," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No.2), pp. 561-567 (2001).	
	164	KAO, ET AL., "Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: in vitro Studies with Mouse Skin in Organ Culture," Journal of Pharmacology and Experimental Therapeutics, Vol. 241 (No. 2), pp. 482-487 (May 1987).	
	165	FINDLAY, ET AL., "Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 68 (No. 2), pp. 369-373 (February 1989).	
SAJ	166	ERNESTI, ET AL., "Absorption and Metabolism of Topically Applied Testosterone in an Organotypic Skin Culture," Skin Pharmacology, Vol. 5 (No. 3), pp. 146-153 (1992).	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/703,753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
		Attorney Docket Number	01736349
Sheet	14	of	21

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAG	167	CHOI, ET AL., "Transdermal Dihydrotestosterone Therapy and its Effects on Patients with Microphallus," Journal Of Urology, Vol. 150 (No. 2) (Part 2), pp. 657-660 (August 1993).	
	168	Testosterone, Chapters 1, 6-16 (1999).	
	169	TSAI, ET AL., "Metabolic Approaches to Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors," Journal of Pharmaceutical Sciences, Vol. 85 (No. 6), pp. 643-648 (June 1996).	
	170	MEIKLE, ET AL., "Familial Effects on Plasma Sex-Steroid Content in Man: Testosterone, Estradiol and Sex-Hormone-Binding Globulin," Metabolism, Vol. 31 (No. 1), pp. 6-9 (January 1982).	
	171	SHANBHAG, ET AL., "The Temperature Dependence of the Binding of 5 Alpha-Dihydrotestosterone, Testosterone and Estradiol to the Sex Hormone Globulin (SHBG) of Human Plasma," J. Steroid Biochem., Vol. 24 (No. 2), pp. 549-555 (February 1986).	
	172	BELGOROSKY, ET AL., "Changes in Serum Sex Hormone-Binding Globulin and in Serum Non-Sex Hormone-Binding Globulin-Bound Testosterone During Prepuberty in Boys," J. Steroid Biochem., Vol. 27 (Nos. 1-3), pp. 291-295 (1987).	
	173	KORENMAN, ET AL., "Androgen Therapy of Hypogonadal Men with Transscrotal Testosterone Systems," American Journal Of Medicine, Vol. 83 (No. 3), pp. 471-478 (September 1987).	
	174	MITCHELL, ET AL., "Age Related Changes in the Pituitary-Testicular Axis in Normal Men; Lower Serum Testosterone Results from Decreased Bioactive LH Drive," Clinical Endocrinology (OXF), Vol. 42 (No. 5), pp. 501-507 (May 1995).	
	175	NANKIN, ET AL., "Decreased Bioavailable Testosterone In Aging Normal and Impotent Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 6), pp. 1418-1420 (December 1986).	
	176	TENOVER, ET AL., "The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clomiphene Citrate," Journal Of Clinical Endocrinology And Metabolism, Vol. 65 (No. 6) pp. 1118-1126 (December 1987).	
SAG	177	WINTERS, ET AL., "The Gonadotropin-Suppressive Activity of Androgen is Increased in Elderly Men," Metabolism, Vol. 33 (No. 11), pp. 1052-1059 (November 1984).	

Examiner Signature	<i>SAG</i>	Date Considered	5/21/02
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

APR 16 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 15 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Citation No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAG	178	MEIKLE, ET AL., "Enhanced Transdermal Delivery of Testosterone Across Nonscrotal Skin Produces Physiological Concentrations of Testosterone and Its Metabolites in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 3), pp. 623-628 (March 1992).	
	179	WINTERS, ET AL., "Serum LH Concentrations in Hypogonadal Men During Transdermal Testosterone Replacement Through Scrotal Skin: Further Evidence That Ageing Enhances Testosterone Negative Feedback. The Testoderm Study Group," Clinical Endocrinology (OXF), Vol. 47 (No. 3), pp. 317-322 (September 1997).	
	180	BOYLE, ET AL., "Serum Testosterone Measurements," American Journal Of Clinical Pathology, Vol. 81 (No. 6), pp. 754-761 (June 1984).	
	181	HOLOWNIA, ET AL., "A Clinical Evaluation of A Direct Radioimmunoassay of Testosterone," Clinical Chimica Acta, Vol. 214 (No. 1), pp. 31-43 (January 31, 1993).	
	182	BELGOROSKY, ET AL., "Progressive Decrease in Serum Sex Hormone-Binding Globulin from Infancy to Late Puberty in Boys," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 2), pp. 510-512 (August 1986).	
	183	VALERO-POLITI, ET AL., "Daily Rhythmic and Non-Rhythmic Variations of Follitropin, Lutropin, Testosterone, and Sex-Hormone-Binding Globulin in Men," Eur. J. Clin. Chem. Clin. Biochem., Vol. 34 (No. 6), pp. 455-462 (June 1996).	
	184	VALERO-POLITI, ET AL., "Annual Rhythmic Variations of Follitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men," Clinica Chimica Acta, Vol. 271 (No. 1), pp. 57-71 (March 9, 1998).	
	185	LONGCOPE, ET AL., "Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 71 (No. 6), pp. 1442-1446 (December 1990).	
	186	BELGOROSKY, ET AL., "Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones," J. Steroid Biochem., Vol. 18 (No. 6), pp. 783-787 (1983).	
	187	LEWIS, ET AL., "Proceedings: Age-Related Changes in Serum 5alpha-dihydrotestosterone and Testosterone in Normal Men," Journal Of Endocrinology, Vol. 67 (No. 2), pg. 15P (November 1975).	
SAG	188	PIRKE, ET AL., "Age Related Changes and Interrelationships Between Plasma Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males," ACTA Endocrinologica (COPENH), Vol. 74 (No. 4), pp. 792-800 (December 1973).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

APR 10 2002

RECEIVED

APR 16 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(use as many sheets as necessary)

Sheet 16 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	189	MASTERS, ET AL., "Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol," Clinical Chemistry, Vol. 35 (No. 6), pp. 979-984 (June 1989).	TECH CENTER 1600/2900
	190	WANG, ET AL., "Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 53 (No. 5), pp. 1021-1024 (November 1981).	TECH CENTER 1600/2900
	191	ZMUDA, ET AL., "Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men," Metabolism, Vol. 45 (No. 8), pp. 935-939 (August 1996).	TECH CENTER 1600/2900
	192	GAIDANO, ET AL., "Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty," Clinical Chimica Acta, Vol. 100 (No. 2), pp. 91-97 (January 15, 1980).	TECH CENTER 1600/2900
	193	Definition of Isopropyl Myristate (5103), The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals, Eleventh Edition, p. 821 (1989).	TECH CENTER 1600/2900
	194	GENNARO, ET AL., Remington's Pharmaceutical Sciences, Eighteenth Edition, pp. 1305, 1314-1315 (1990).	TECH CENTER 1600/2900
	195	LANGTRY, ET AL., "Sildenafil - A Review of its Use in Erectile Dysfunction," Drugs, Vol. 57 (No. 6), pp. 967-989 (1999).	TECH CENTER 1600/2900
	196	MORELAND, ET AL., "Sildenafil, A Novel Inhibitor of Phosphodiesterase Type 5 In Human Corpus Cavernosum Smooth Muscle Cells," Life Sciences, Vol. 62 (No. 20) pp. PL309-318 (1998).	TECH CENTER 1600/2900
	197	FAHRNER, ET AL., "Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG)," International Journal Of Sports Medicine, Vol. 19 (No. 1), pp. 12-15 (January 1998). [Abstract]	TECH CENTER 1600/2900
	198	BARTSCH, "Interrelationships Between Sex Hormone-Binding Globulin and Testosterone, 5 alpha-Dihydrotestosterone and Oestradiol-17 beta in Blood of Normal Men," Maturitas, Vol. 2 (No. 2), pp. 109-118 (July 1980). [Abstract]	TECH CENTER 1600/2900
	199	WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," Clinical Endocrinology, Vol. 54, pp. 1-13 (2001).	TECH CENTER 1600/2900

Examiner
Signature

Date

Considered

5/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 1 8 2002

RECEIVED
APR 1 6 2002

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/703.753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
Sheet	17 of 21	Attorney Docket Number	01736349

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJD	200	GOOREN, "A Ten-Year Safety Study of the Oral Androgen Testosterone Undecanoate," J. Androl., Vol. 15 (No. 3), pp. 212-215 (May-June 1994). [Abstract]	
	201	MAZER, "New Clinical Applications of Transdermal Testosterone Delivery in Men and Women," J. Controlled Release, Vol. 65 (No. 1-2), pp. 303-315 (March 1, 2000). [Abstract]	
SJD	202	ITOH, ET AL., "The Assessment of Bioavailable Androgen Levels from the Serum Free Testosterone Level," Nippon Naibunpi Gakkai Zasshi, Vol. 67 (No. 1), pp. 23-32 (January 20, 1991). [Abstract]	
	203	Male Hormone Patch Approved, Nupharm, http://www.nupharm.com/malehorn.htm .	
	204	"SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available," International Association of Physicians in AIDS Care, http://www.iapac.org/clinimgt/compnews/sb061297.html (June-12, 1997).	
	205	"Impotence Treatments," Impotence World Association, http://www.impotenceworld.org/treatment.htm (2000).	
	206	"Andro-Gel," Netrition, http://www.netrition.com/andro_gel_page.html (1997-1998).	
	207	"Cellegy Pharmaceuticals Market Opportunities," CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market.html (1999).	
	208	"Prospectus - Cellegy Pharmaceuticals, Inc.," OPPENHEIMER & CO., pp. 1-21-28 (1997).	
	209	The Testosterone Source, http://www.testosteronesource.com (1998).	
	210	BONNEY, "Hormone Replacement Therapy for Men," American Clinical Laboratory, http://iscpubs.com/pubs/acl/acl1197.html (November/December 1997).	

Examiner Signature	Date Considered
SJD	5/24/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 16 2002

RECEIVED
APR 16 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/703,753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
Sheet 18 of 21	Attorney Docket Number	01736349	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	211	Andropausal, Los Gatos Longevity Institute, http://www.antiaging.com/andropause.html (1998).	
	212	TestoCreme - A Natural Transdermal Testosterone Replacement Therapy, www.testocreme.com .	
SJ	213	WANG, ET AL., "Pharmacokinetics Of Transdermal Testosterone Gel in Hypogonadal Men," ENDO '98 SUBMISSION PROGRAM, 1998N ABSTRACT FORM.	
	214	SWERDLOFF, ETAL., "Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men," 2347 Male Reproductive Poster Session, Board 578 (June 22, 2000).	
	215	WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," 2348 Male Reproductive Poster Session, Board 579 (June 22, 2000).	
	216	WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," Basic Science: Reproduction-Gonadal Control (Male), Male Reproduction Oral Session, No. 1360 (June 24, 2000).	
	217	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www. INCIID.com (August 19, 1998).	
SJ	218	RIGGS, "Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel," Unimed News Release, pp. 1-2 (March 31, 1997).	
	219	Androgel 1% (testosterone gel) CII, www.Androgel.com , pp. 1-2.	
SJ	220	VERGEL, "Anabolic Steroids: A Practical Guide," CRIA Update, Vol. 7 (No. 3) (Summer 1998).	
	221	MOONEY, "Frequency of Administration - Testosterone & Nandrolone," Vol. 1 (No. 4), www.medibolics.com (Downloaded-10/8/98).	

Examiner Signature	<i>SJ</i>	Date Considered	5/2/02
--------------------	-----------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

APR 16 2002

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 19 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	222	Anabolic Steroids, Project Inform, Anabolic Steroids Quick Sheet (December 1997).
	223	"Anabolic Steroid Boosts Weight," GMHC Treatment Issues, Vol. 10, No. 9 (September 1996).
	224	Anabolic Steroids, Project Inform Hotline Handout, www.projinf.org. (Downloaded 10/8/98).
	225	Anabolic Steroids - A Simple Facts Sheet From The Network, www.network/simple/steroids (Downloaded 10/27/98).
	226	USP Drug Information - Anabolic Steroids (Systemic), Mayo Clinic, www.mayohealth.org (Downloaded 10/8/98).
	227	MOONEY, "Anabolic Steroids For AIDS Therapy: Differences Between Analogs," No. 1, www.digiweb.com. (July 1998):
	228	Testocrema - No Shots, No Pills, No Patches, www.testocrema.com (Downloaded 7/10/00).
	229	"ENDO 99: Testosterone Patch Effective For Diminished Sexual Function in Surgically Menopausal Women," www.pslgroup.com (June 15, 1999).
	230	"Data Supports Safety of Estratest For Men," Doctor's Guide, www.pslgroup.com (March 9, 1998).
	231	"Testosterone's Role in the Female Sex Drive," USA Today News, www.usatoday.com (April 8, 1996).
	232	"Alternative to Viagra For Women?," www.mdhealthline.com (Downloaded 8/7/00).

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 16 2002

RECEIVED
APR 16 2002

RECEIVED
APR 16 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 20 of 21

Complete if Known

Application Number 09/703,753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SJD	233	"Never Too Buff," Time Europe, www.time.com, Vol. 155 (No. 16) (April 24, 2000).	TECH CENTER 1600/2900
	234	Gefael, Graeme's Testosterone Page, www.voyager.co.nz (5/12/00).	TECH CENTER 1600/2900
	235	Estrogel, www.netdoktor.dk/medicin/Fakta/Estrogel (Downloaded 6/26/01).	TECH CENTER 1600/2900
	236	La Sexualite . . . , L'Androgel, Le Gel Miracle, www.aci-multimedia.net/feminin/androgel (Downloaded 5/9/01).	TECH CENTER 1600/2900
	237	Stehli, et al., Info . . . , Info . . . , Info . . . - Androgel, www.mageos.ifrance.com/nade38/androgel (Downloaded 5/9/01).	TECH CENTER 1600/2900
	238	CHERRIER, ET AL., "T-Gel Study: Cognitive Effects of Exogenous Testosterone Manipulation in Hypogonadal Men" (6/7/99).	TECH CENTER 1600/2900
	239	"Bentley Pharmaceuticals Announces Research and Licensing Agreements For Intranasal Pain Management and Topical Hormone Replacement Therapy," www.bentleypharm.com (downloaded 11/17/01).	TECH CENTER 1600/2900
	240	"Testosterone Gel May Help Men with Low Sex Drive," WRAL ONLINE, http://www.wral-tv.com/features/healthteam/1997/0814-tgel/ (August 14, 1997).	TECH CENTER 1600/2900
	241	"Testocreme Transdermal Testosterone Is New," Preventive Medicine Clinic Of Monterey, http://www.wellnessmd.com/testo.html.	TECH CENTER 1600/2900
	242	"SEPA Testosterone Transdermal Gel Receives Application by FDA," Doctor's Guide Global Edition, http://pslgroup.com/dg/123aa.htm (January 15, 1997).	TECH CENTER 1600/2900
	243	Press Release - 10/21/99 -- MacroChem Awarded U.S. Patent Covering Transdermal Hormone Replacement Incorporating Proprietary SEPA Technology and Hormonally Active Drugs Such as Testosterone, Estradiol and Progesterone, http://www.mchm.com/press/pr24.asp (October 21, 1999).	TECH CENTER 1600/2900

Examiner Signature

SJD

Date

Considered

5/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
APR 16 2002

RECEIVED
APR 16 2002

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/703.753
		Filing Date	November 1, 2000
		First Named Inventor	Robert E. Dudley
		Group Art Unit	1617
		Examiner Name	S. Jiang
		Attorney Docket Number	01736615
Sheet	21	of	21

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	244	AndrosteDERM, http://www.gethuge.net/androderm1.htm .	TECH CENTER 1600/2900
	245	MANOS, "FDA Approves Gel to Treat Low Testosterone Levels," www.testocrema.com (Downloaded 5/09/01).	APR 1 6 2002
	246	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www.INCIID.com (August 19, 1998).	
SJ	247	LACAYO, "Are You Man Enough?," Time Europe, www.Time.com , Vol. 155, No. 16 (April 24, 2000).	
	248	"MacroChem Accelerates Development of Top For Impotence," www.pslgroup.com (April 10, 1997).	TECH CENTER 1600/2900
SJ	249	BRADLEY, "Potential Expanded Indications for Androgen Treatment," The Endocrine Society, No. 166 (ENDO 2000).	APR 6 2002
	250	WANG, ET AL., "New Androgen Formulations," The Endocrine Society, No. 167 (ENDO 2000).	
	251	WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," The Endocrine Society, No. 1360 (ENDO 2000).	TECH CENTER 1600/2900
	252	WITTERT, ET AL., "Androgen Deficiency in Aging Men," The Endocrine Society, No. 1626 (ENDO 2000).	
SJ	253	BRILL, ET AL., "Single and Joint Impact of One-Month of Transdermal Testosterone (T) and/or Recombinant Human Growth Hormone (rhGH) Supplementation on Body Composition, Strength, Balance, Function and Muscle IGF-I and Androgen Gene Expression in Healthy Older Men: A Prospective Randomized Double-Blind Crossover," The Endocrine Society, No. 1647 (ENDO 2000).	TECH CENTER 1600/2900
			APR 1 6 2002

Examiner Signature	<i>SJ</i>	Date Considered	5/21/02
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

RECEIVED

RECEIVED